Neuroblastoma Recurrent

Oncology·MeSH: Recurrence

Prevalence

30.0 / 100K

6 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 2(6)

Drug	Company
hu14.18k322a	GH Research PLC (GHRS)
hu14.18K322A	CG Oncology, Inc. (CGON)
n803	GH Research PLC (GHRS)
N803	CG Oncology, Inc. (CGON)
sargramostim	GH Research PLC (GHRS)
Sargramostim	CG Oncology, Inc. (CGON)

Compare drugs

hu14.18k322a vs n803 hu14.18k322a vs sargramostim

Frequently asked questions

How many drugs are in development for Neuroblastoma Recurrent?

BioSniper tracks 6 drugs in development for Neuroblastoma Recurrent across 2 companies.

How many clinical trials target Neuroblastoma Recurrent?

There are 1 clinical trial targeting Neuroblastoma Recurrent tracked by BioSniper.

What is the prevalence of Neuroblastoma Recurrent?

The estimated prevalence of Neuroblastoma Recurrent is approximately 30.0 per 100,000 population.

Deep-dive into Neuroblastoma Recurrent

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Neuroblastoma Recurrent — Drugs in Development & Clinical Trials | BioSniper